Table 2 Baseline criteria of the two groups after PSM

Patients, n

47

47

Age (year)^a

71.7 ± 6.4

72.3 ± 6.8

0.662

Disease duration (year)^b

5.3 ± 2.2

5.0 ± 1.9

0.501

Anticoagulants^c

12 (25.5%)

8 (17.0%)

0.503

Alpha blockers^c

22 (46.8%)

26 (55.3%)

0.532

5ARIs alone or combined with alpha blockers^c

16 (34.0%)

15 (31.9%)

1.000

Urogenital complications

 With acute urinary retention^c

13 (27.7%)

14 (29.8%)

1.000

 With gross haematuria^c

16 (34%)

15 (31.9%)

1.000

 With bladder stones^c

7 (14.9%)

8 (17.0%)

1.000

 With bladder trabeculae or chambers^c

27 (57.4%)

25 (53.2%)

0.832

Prostate volume (ml)^b

65.3 ± 20.6

67.0 ± 10.8

0.369

IPSS^b

25.3 ± 4.9

25.6 ± 4.7

0.473

Qob^b

4.8 ± 0.7

4.9 ± 0.8

0.421

Qmax (ml/s)^b

6.6 ± 2.4

6.7 ± 2.3

0.941

PVR (ml)^b

148.0 ± 140.7

145.4 ± 130.8

0.820

PSA (ng/ml)^b

3.9 ± 2.6

3.8 ± 2.0

0.992